Rixubis

nonacog gamma · Baxalta Innovations GmbH
AUTHORISED IN THE EU

What Rixubis is used for

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Rixubis
Active substance
nonacog gamma
Disease area
Hemophilia B
Medicine group
Antihemorrhagics
ATC code
B02BD04
Marketing authorisation holder
Baxalta Innovations GmbH
Authorised in the EU since
2014

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Rixubis used for?

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

What is the active substance in Rixubis?

Rixubis contains nonacog gamma.

Who makes Rixubis?

The EU marketing authorisation holder is Baxalta Innovations GmbH.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.